1. Home
  2. VHUB vs ICCC Comparison

VHUB vs ICCC Comparison

Compare VHUB & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VenHub Global Inc. Common Stock

VHUB

VenHub Global Inc. Common Stock

N/A

Current Price

$0.40

Market Cap

80.6M

Sector

N/A

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.69

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VHUB
ICCC
Founded
2000
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.6M
93.1M
IPO Year
2025
1995

Fundamental Metrics

Financial Performance
Metric
VHUB
ICCC
Price
$0.40
$9.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 259.7K
11.2K
Earning Date
11-14-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 53.85
EPS
N/A
★ 0.41
Revenue
$864,450.00
★ $26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$23.78
Revenue Growth
N/A
★ 51.64
52 Week Low
$0.38
$4.52
52 Week High
$15.34
$12.10

Technical Indicators

Market Signals
Indicator
VHUB
ICCC
Relative Strength Index (RSI) 30.50 42.87
Support Level N/A $9.42
Resistance Level $0.80 $10.16
Average True Range (ATR) 0.06 0.23
MACD -0.01 -0.01
Stochastic Oscillator 6.75 16.26

Price Performance

Historical Comparison
VHUB
ICCC

About VHUB VenHub Global Inc. Common Stock

Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: